Ironwood Pharmaceuticals, Inc. (IRWD) Shares Bought by D. E. Shaw & Co. Inc.
D. E. Shaw & Co. Inc. raised its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 199.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 719,442 shares of the biotechnology company’s stock after acquiring an additional 479,462 shares during the quarter. D. E. Shaw & Co. Inc. owned approximately 0.47% of Ironwood Pharmaceuticals worth $7,453,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. CWM LLC purchased a new position in Ironwood Pharmaceuticals in the fourth quarter worth approximately $31,000. Pacer Advisors Inc. purchased a new position in Ironwood Pharmaceuticals in the third quarter worth approximately $177,000. First Manhattan Co. purchased a new position in Ironwood Pharmaceuticals in the fourth quarter worth approximately $133,000. Bank of Montreal Can grew its position in Ironwood Pharmaceuticals by 426.9% in the fourth quarter. Bank of Montreal Can now owns 16,846 shares of the biotechnology company’s stock worth $175,000 after acquiring an additional 13,649 shares during the period. Finally, Dimensional Fund Advisors LP purchased a new position in Ironwood Pharmaceuticals in the fourth quarter worth approximately $252,000. 96.68% of the stock is owned by institutional investors and hedge funds.
NASDAQ:IRWD opened at $13.29 on Wednesday. Ironwood Pharmaceuticals, Inc. has a 12-month low of $9.07 and a 12-month high of $21.20.
In other Ironwood Pharmaceuticals news, Director Lawrence S. Olanoff sold 2,000 shares of the firm’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $14.41, for a total value of $28,820.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Mark G. Currie sold 275,000 shares of the firm’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $13.26, for a total value of $3,646,500.00. Following the completion of the sale, the insider now owns 577,980 shares in the company, valued at $7,664,014.80. The disclosure for this sale can be found here. Over the last quarter, insiders sold 403,872 shares of company stock valued at $5,281,958. 7.63% of the stock is currently owned by company insiders.
Several research analysts have recently commented on the company. ValuEngine lowered Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, December 12th. BidaskClub lowered Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, February 25th. BTIG Research set a $19.00 price target on Ironwood Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, February 14th. HC Wainwright set a $12.00 price target on Ironwood Pharmaceuticals and gave the stock a “sell” rating in a research report on Monday, December 10th. Finally, Wood & Company assumed coverage on Ironwood Pharmaceuticals in a research report on Tuesday, February 26th. They set a “buy” rating for the company. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $17.05.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.
Featured Article: Outstanding Shares
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.